Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia

Quizartinib advances overall survival in acute myeloid leukaemia patients

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma

Lack of access to new cancer medicines in LMICs

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients

ASCO 2022: Breast cancer highlights

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib